KRAS and ovarian neoplasm: Hyperactivation of MEK1/2 and ERK1/2 is often caused by activating mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) and V-Raf murine sarcoma viral oncogene homolog B (BRAF) genes, and therefore was considered to be confined to low-grade ovarian tumors only [14,15].